Header cover image

Japanese (NIKKEI) Biotech Industry Analysis

UpdatedJun 30, 2022
DataAggregated Company Financials
  • 7D-0.4%
  • 3M-19.9%
  • 1Y-54.4%
  • YTD-29.3%

In the last week, the Biotech industry is up 4.8%, with PeptiDream up 13%. Meanwhile, AnGes actually underperformed within the industry, shrinking 5.6% in the last week. However, the industry is down 54% over the past year. Looking forward, earnings are forecast to grow by 16% annually.

Industry Valuation and Performance

Has the Japanese Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPE
Fri, 01 Jul 2022JP¥887.9bJP¥171.3b-JP¥16,112,943,000.0020.6x
Sun, 29 May 2022JP¥868.6bJP¥169.3b-JP¥13,461,721,000.0010.8x
Tue, 26 Apr 2022JP¥987.2bJP¥164.2b-JP¥13,043,295,000.0014x
Thu, 24 Mar 2022JP¥1.1tJP¥164.2b-JP¥13,044,654,000.0015.2x
Sat, 19 Feb 2022JP¥1.1tJP¥159.9b-JP¥9,023,909,000.0016x
Mon, 17 Jan 2022JP¥1.2tJP¥163.5b-JP¥5,447,358,000.0017.4x
Wed, 15 Dec 2021JP¥1.2tJP¥163.5b-JP¥6,334,358,000.0018.3x
Fri, 12 Nov 2021JP¥1.3tJP¥153.9b-JP¥13,495,269,000.0019x
Sun, 10 Oct 2021JP¥1.4tJP¥147.6b-JP¥12,269,440,000.0022.8x
Tue, 07 Sep 2021JP¥1.7tJP¥147.9b-JP¥14,140,440,000.0025.6x
Thu, 05 Aug 2021JP¥1.6tJP¥148.3b-JP¥14,096,440,000.0023.3x
Sun, 09 May 2021JP¥1.8tJP¥130.4b-JP¥17,249,632,000.0038.5x
Wed, 10 Feb 2021JP¥2.0tJP¥112.5b-JP¥20,970,087,000.00126.5x
Tue, 03 Nov 2020JP¥1.7tJP¥90.4b-JP¥27,284,135,000.00213.4x
Fri, 07 Aug 2020JP¥1.6tJP¥81.4b-JP¥26,122,602,000.00130.9x
Thu, 30 Apr 2020JP¥1.5tJP¥80.7b-JP¥31,890,297,000.0076.2x
Sun, 02 Feb 2020JP¥1.6tJP¥77.2b-JP¥30,683,316,000.0085.3x
Wed, 06 Nov 2019JP¥1.7tJP¥79.8b-JP¥25,898,343,000.00146.7x
Sat, 10 Aug 2019JP¥1.7tJP¥79.0b-JP¥17,211,601,000.0061.6x
Median PE Ratio


Total Market Cap: JP¥1.6tTotal Earnings: -JP¥15,954,601,000.00Total Revenue: JP¥78.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Japanese Biotech Industry Median PE3Y Average 81.4x202020212022
Current Industry PE
  • Investors are pessimistic on the industry, indicating that they anticipate long-term growth rates will be lower than they have historically.
  • The industry's 3-year average PS ratio 15.4x is higher than the industry's current PS ratio of 5.2x.
Past Earnings Growth
  • Losses for companies in the Biotechnology industry have mostly stayed the same over the last three years.
  • Meanwhile revenues for these companies have grown 30% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, losses haven't seen much improvement.

Industry Comparison

How does Japanese Biotech compare with similar industries?

JP Market0.26%
Industry PEThere is insufficient data on the sub-industries of this industry.
Forecasted GrowthThere is insufficient data on the sub-industries of this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
4587 PeptiDreamJP¥1.42k6.4%
7774 Japan Tissue EngineeringJP¥601.004.5%
4571 NanoCarrierJP¥283.003.7%
4883 Modalis TherapeuticsJP¥506.001.8%
4575 CanBasJP¥649.002.9%
Simply Wall St
Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News